Free Trial
NASDAQ:APLT

Applied Therapeutics (APLT) Stock Price, News & Analysis

Applied Therapeutics logo
$0.44 -0.02 (-4.47%)
As of 04:00 PM Eastern

About Applied Therapeutics Stock (NASDAQ:APLT)

Key Stats

Today's Range
$0.42
$0.47
50-Day Range
$0.30
$0.60
52-Week Range
$0.30
$10.62
Volume
2.46 million shs
Average Volume
3.33 million shs
Market Capitalization
$61.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.10
Consensus Rating
Moderate Buy

Company Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

APLT MarketRank™: 

Applied Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 181st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Applied Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Applied Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Applied Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Applied Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Applied Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Applied Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.18% of the outstanding shares of Applied Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Applied Therapeutics has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in Applied Therapeutics has recently decreased by 1.68%, indicating that investor sentiment is improving.
  • Dividend Yield

    Applied Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Applied Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.18% of the outstanding shares of Applied Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Applied Therapeutics has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in Applied Therapeutics has recently decreased by 1.68%, indicating that investor sentiment is improving.
  • News Sentiment

    Applied Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Applied Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    Only 5 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,561.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of Applied Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Applied Therapeutics' insider trading history.
Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Stock News Headlines

What is William Blair's Estimate for APLT FY2025 Earnings?
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Leerink Partnrs Issues Positive Estimate for APLT Earnings
See More Headlines

APLT Stock Analysis - Frequently Asked Questions

Applied Therapeutics' stock was trading at $0.8562 at the beginning of the year. Since then, APLT stock has decreased by 49.1% and is now trading at $0.4355.
View the best growth stocks for 2025 here
.

Applied Therapeutics, Inc. (NASDAQ:APLT) posted its quarterly earnings data on Monday, April, 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.06. The company earned $0 million during the quarter, compared to the consensus estimate of $0.61 million.

Applied Therapeutics (APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

Top institutional investors of Applied Therapeutics include Propel Bio Management LLC (7.97%), T. Rowe Price Investment Management Inc. (7.33%), Alyeska Investment Group L.P. (2.19%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder and Stacy J Kanter.
View institutional ownership trends
.

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

Last Earnings
4/14/2025
Today
5/20/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APLT
Fax
N/A
Employees
30
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$6.10
High Stock Price Target
$14.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+1,229.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-119,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$455,000.00
Price / Cash Flow
N/A
Book Value
($0.20) per share
Price / Book
-2.30

Miscellaneous

Free Float
106,349,000
Market Cap
$64.98 million
Optionable
Optionable
Beta
2.00

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:APLT) was last updated on 5/20/2025 by MarketBeat.com Staff
From Our Partners